drugset / Trial / NCT04328714
Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease
Non-randomizedSequentialOpen-labelTreatment
Summary
The protocol is a phase I open label study evaluating the safety and feasibility of peri-transplant infusion of freshly expanded interferon gamma primed MSCs in adult and pediatric patients undergoing HCT for acute leukemia and myelodysplastic syndrome (MDS).
Timeline
- Start
- 2021-12-02
- Primary completion
- 2022-07-20
- Completion
- 2022-07-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells | Cell therapy | 2e+06 cells/kg | Intravenous |
| Subject | Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells | Cell therapy | 5e+06 cells/kg | Intravenous |
| Subject | Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells | Cell therapy | 1e+07 cells/kg | Intravenous |